“From its debut in 1925, a Rolls-Royce Phantom has been the choice of the world’s most influential and powerful men and women, and as a result, a constant presence at history’s most defining moments” - Torsten Müller-Ötvös, Chief Executive Officer, Rolls-Royce Motor Cars.
Rolls-Royce Motor Cars today unveiled the eighth generation Phantom at a gala reception in London. Flanked by seven great Phantoms representing the first seven generations of the car, Phantom VIII is the 21st Century incarnation of the world’s longest running automotive nameplate and what is inarguably the “best car in the world.”
This wholly new contemporary design of Rolls-Royce Phantom DNA offers an all-new aluminium ‘Architecture of Luxury’ which underpins the Phantom and ensures the architectural and proportional lineage of Rolls-Royce while delivering a new level of ‘Magic Carpet Ride:’ lighter, stiffer, quieter than ever.
To view the multimedia release go to:
https://www.multivu.com/players/English/8142951-eighth-generation-rolls-royce-phantom-unveiled/
The Dreaming Tree Wines, a California wine brand from award-winning winemaker Sean McKenzie and musician Dave Matthews, is proud to announce it has hit $1 Million in charitable donations to environmental organizations The Wilderness Society and Living Lands & Waters in support of reforestation and conservation, a goal it set out to achieve six years ago when the brand was launched.
The Dreaming Tree began with a mission to create sustainably produced and packaged wines, as well as ensure that a portion of proceeds from every bottle purchased benefits organizations on the front lines of environmental conservation by planting trees and protecting the nation’s forests. “The more work we can do like this in towns and cities around the world, the more we can change the outcome of the future of those communities,” says The Dreaming Tree Wines co-conspirator Dave Matthews. “I really feel grateful that there are organizations like The Wilderness Society and Living Lands & Waters that can turn this into a reality.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8127651-dreaming-tree-dave-matthews-wine-environmental-conservation-charity-sustainability/
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of the Fluzone® (Influenza Vaccine) portfolio for the 2017-2018 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA). Sanofi Pasteur has begun distributing initial shipments, representing the first of nearly 70 million total doses of seasonal influenza vaccine manufactured by the company for this upcoming influenza season. Widespread shipment of Fluzone Quadrivalent, Fluzone High-Dose and Fluzone Intradermal Quadrivalent vaccine to health care provider offices, pharmacies and other immunizers will begin in early August to support fall immunization campaigns.
“As we enter the Swiftwater site’s 120th year, it reminds us of our innovation and growth as we came to understand the science of influenza and its impact on human health,” said David P. Greenberg, M.D., Associate Vice President and Regional Medical Head North America, Sanofi Pasteur. “Influenza can be especially severe for the most vulnerable populations, including the elderly, young children and those with compromised immune systems; however, it can also have a serious health impact on otherwise healthy individuals. Sanofi Pasteur is and always has been deeply committed to improving public health by continuously striving to develop new vaccines and on improving existing ones.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8081151-sanofi-pasteur-influenza-vaccine-first-shipment-2017/
Abila, the leading provider of software and services to nonprofits, associations, and government entities, announced today findings from its Nonprofit Finance Study: Managing Growth. This study explores the trends and challenges associated with nonprofit growth, including how organizations plan to grow in the next few years, growth’s impact on risk management and compliance, and the difficulties maintaining organizational culture during growth.
“Approximately 80 percent of surveyed nonprofits say they plan to grow in the next 12 to 18 months,” said Dan Murphy, senior manager of fund accounting strategy for Abila, and study co-author. “However, oftentimes, with growth comes increased complexity. For example, managing risk, maintaining compliance, and retaining an organization’s unique culture becomes more challenging as organizations adopt a wide variety of growth strategies. Those nonprofits that understand and plan for growth now and in the near future will be primed for success.”
To view the multimedia release go to:
https://www.multivu.com/players/English/7858254-abila-nonprofit-finance-study/
Dornier MedTech® America, a global medical device company and the pioneer of Extracorporeal Shock Wave Lithotripsy (ESWL®), has received FDA clearance to market the Delta® III. This is the latest generation of the world’s best-selling and most clinically cited lithotripter, the Delta II.
To view the multimedia release go to:
https://www.multivu.com/players/English/8134451-dornier-medtech-delta-iii-kidney-stone-lithotripter/
DIY Network® heads north to New England and the shores of beautiful Lake Champlain for the first-ever Ultimate Retreat, which has been reimagined after ten successful years as DIY Network Blog Cabin. The new project invites viewers to follow the demolition and renovation process room by room as a home in a spectacular vacation destination is transformed into a show-stopping retreat. Beginning today, fans can take a virtual tour of this cozy wooded escape in Burlington, Vermont to see what authentic waterside living is all about.
From Monday, August 7, fans can enter the sweepstakes each day through 5 p.m. ET Wednesday, September 27 for a chance to win the DIY Network Ultimate Retreat™ Giveaway 2017, including the fully furnished and completely renovated residence plus $50,000 from national mortgage lender Quicken Loans®.
To view the multimedia release go to:
https://www.multivu.com/players/English/8041052-diy-network-ultimate-retreat-2017-vermont/
Renault Zoe. Renault has managed to increase the Zoe's range with an impressive 41-kWh battery, called the R90, that gives an official NEDC range of 403 kilometers (250 miles). Sure, the NEDC range is a optimistic fiction concocted by European regulators – something that even Renault admits – but the new Zoe's real-world range should be around 200 km (124 miles) in the winter and 300 km (186 miles) in the summer. Compared to the first-gen Zoe's 250 km (155 mile) NEDC range, this is a tremendous improvement.
Keyword : renault zoe ze 40, renault zoe ze 40 review, renault zoe zen, renault zoe 2017, renault zoe review, renault zoe 2016, renault zoe 400km, renault zoe electric car, renault zoe acceleration, renault zoe 2017 review, renault zoe 40, renault zoe crash test, renault zoe review 2016, renault zoe, renault zoe app, renault zoe ad, renault zoe argentina, renault zoe autoweek, renault zoe autonomie
2017 Long range Renault Zoe EV A practical winner First Drive, That's because Renault has managed to increase the Zoe's range with an impressive 41-kWh battery, called the R90, that gives an official NEDC range of 403 kilometers (250 miles). Sure, the NEDC range is a optimistic fiction concocted by European regulators – something that even Renault admits – but the new Zoe's real-world range should be around 200 km (124 miles) in the winter and 300 km (186 miles) in the summer. Compared to the first-gen Zoe's 250 km (155 mile) NEDC range, this is a tremendous improvement.
Volvo Cars, the premium car maker best known for its leadership in safety, has teamed up with three-time Pulitzer Prize-winning photographer and artist Barbara Davidson for a world-first - using the on-board safety cameras of the new Volvo XC60 to create a special collection of photographs.
This is the first time ever that a car is used as a camera by a photographer. Davidson’s collection of around 30 photographs, taken through the lenses of the XC60’s on-board safety cameras, captures life on the streets of the Danish capital Copenhagen from a completely fresh perspective.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8129151-volvo-cars-exhibition-life-city-xc60/
For the 22,000 children who attend diabetes camp each year, feelings of isolation that may accompany type 1 diabetes can be overcome by fun experiences and new friends who say, “you are not alone.” Lilly Diabetes understands the importance of the diabetes camp experience for those taking the first steps toward self-management and increased self-confidence. For more than 15 years, Lilly has been at the forefront of support with its Camp Care Package program. This year, Lilly’s diabetes ambassadors, all of whom have type 1 diabetes, will attend camps and share their stories starting July 4 at the Children with Diabetes® Friends for Life® conference.
To view the multimedia release go to:
https://www.multivu.com/players/English/8115051-lilly-diabetes-camp-care-package-speaker-tour/
The JNA Awards proudly announced its highly anticipated list of Honourees or finalists across 10 categories on the sidelines of the June Hong Kong Jewellery & Gem Fair.
The event, now in its sixth year, is a premier awards programme that recognises and celebrates excellence and achievement in the jewellery and gemstone industry, with a focus on advancing the trade in Asia.
This year, close to 100 highly qualified entries from 13 countries and regions, namely mainland China, Fiji, Hong Kong, India, Japan, Malaysia, Singapore, South Korea, Switzerland, Taiwan, Thailand, United Arab Emirates and Vietnam, were received.
To view the multimedia release go to:
https://www.multivu.com/players/English/8126151-jna-awards-2017/
A first-of-a-kind neural stem cell therapy that works with a common cold virus to seek out and attack a lethal and aggressive brain cancer is being tested at Northwestern Medicine in a Phase I clinical trial for patients newly diagnosed with malignant glioma.
The novel drug to treat malignant glioma, notorious for recurring after typical bouts of standard cancer treatment, was developed by a Northwestern scientist and has been approved as an investigational drug by the U.S. Food and Drug Administration. This is only the second time the University has supported and filed an investigational new drug as a sponsor.
To view the multimedia release go to:
https://www.multivu.com/players/English/7944251-northwestern-medicine-stem-cell-trial/
